Docoh
Loading...

TPTX Turning Point Therapeutics

GRANT
Utility
Macrocycles for use in treating disease
12 Oct 21
The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
Filed: 26 Mar 21
APP
Utility
Macrocycles for Use In Treating Disease
12 Aug 21
The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
Filed: 26 Mar 21
APP
Utility
Combination Therapy Involving Diaryl Macrocyclic Compounds
22 Jul 21
The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with a KRAS inhibitor, such as an inhibitor of KRAS G12C.
Wei DENG, Dayong ZHAI, Laura RODON, Brion W. MURRAY, Jingrong J. CUI
Filed: 25 Nov 20
APP
Utility
Macrocyclic Compounds and Uses Thereof
15 Jul 21
The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
Filed: 25 Mar 21
APP
Utility
Macrocycles for Use In Treating Disease
3 Jun 21
The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
Filed: 2 Dec 20
APP
Utility
Combination Therapy Involving Diaryl Macrocyclic Compounds
27 May 21
The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.
Wei DENG, Dayong ZHAI, Laura RODON, Brion W. MURRAY, Jingrong J. CUI, Nathan V. LEE
Filed: 25 Nov 20
GRANT
Utility
Chiral diaryl macrocycles as modulators of protein kinases
18 May 21
Jingrong J. Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Wei Deng, Jane Ung
Filed: 29 May 19
APP
Utility
Diaryl Macrocycle Polymorph
1 Apr 21
This disclosure relates to polymorphs of (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one that are useful in the treatment of disease, such as cancer, in mammals.
Jingrong J. Cui, Evan W. Rogers
Filed: 15 Oct 20
APP
Utility
Macrocyclic Kinase Inhibitors and Their Use
25 Mar 21
The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
Evan W. ROGERS, Jane UNG, Han ZHANG, Jeffrey WHITTEN, Dayong ZHAI, Wei DENG, Jingrong Jean CUI
Filed: 18 Dec 18
APP
Utility
Chiral Diaryl Macrocycles and Uses Thereof
4 Feb 21
This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals.
Jingrong J. CUI, Yishan LI, Evan W. ROGERS, Dayong ZHAI, Wei DENG, Zhongdong HUANG
Filed: 20 Aug 20
APP
Utility
Macrocyclic Compounds for Treating Disease
16 Dec 20
The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
Filed: 4 May 20
GRANT
Utility
Macrocyclic compounds for treating disease
17 Aug 20
The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
Filed: 29 Jan 20
APP
Utility
Diaryl Macrocycles As Modulators of Protein Kinases
8 Jul 20
The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
Filed: 20 Feb 20
GRANT
Utility
Macrocycle kinase inhibitors
22 Jun 20
The present disclosure relates to certain macrocyclic kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same to treat disease.
Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Jane Ung
Filed: 26 Jul 17
APP
Utility
Macrocyclic Compounds for Treating Disease
17 Jun 20
The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
Filed: 29 Jan 20
APP
Utility
Macrocyclic Compounds and Uses Thereof
20 May 20
The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
Jingrong Jean CUI, Evan W. ROGERS, Jane UNG, Jeffrey Whitten, Dayong Zhai, Wei DENG, Xin ZHANG, Zhongdong HUANG, Jing LIU, Han ZHANG
Filed: 25 Jul 18
GRANT
Utility
Diaryl macrocycles as modulators of protein kinases
13 Apr 20
The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
Filed: 28 Nov 18
APP
Utility
Combination Therapy Involving Diaryl Macrocyclic Compounds
18 Dec 19
The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with at least one other cancer therapeutic, such as an EGFR inhibitor.
Jingrong Jean CUI, Dayong ZHAI
Filed: 24 Jan 18
  • 1
Patents are sorted by USPTO publication date, most recent first